` APTO (Aptose Biosciences Inc) vs S&P 500 Comparison - Alpha Spread

A
APTO
vs
S&P 500

Over the past 12 months, APTO has underperformed S&P 500, delivering a return of -73% compared to the S&P 500's +15% growth.

Stocks Performance
APTO vs S&P 500

Loading
APTO
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
APTO vs S&P 500

Loading
APTO
S&P 500
Difference
www.alphaspread.com

Performance By Year
APTO vs S&P 500

Loading
APTO
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Aptose Biosciences Inc vs Peers

S&P 500
APTO
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Aptose Biosciences Inc
Glance View

Market Cap
3.2m USD
Industry
Biotechnology

Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. The company is headquartered in North York, Ontario and currently employs 41 full-time employees. The firm has two clinical-stage investigational products for hematologic malignancies: luxeptinib and APTO-253. The luxeptinib is a mutation agnostic Bruton’s tyrosine kinase (BTK) kinase inhibitor, which is in a Phase I a/b trial in patients with refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies and is in a separate Phase I a/b trial in patients with refractory acute myeloid leukemia (AML). Its APTO-253 is the clinical stage agent that directly targets the Master Regulator of Cell Cycle Entry and Proliferative Metabolism (MYC) oncogene and suppresses its expression, which is in a Phase I a/b clinical trial for the treatment of patients with relapsed.

APTO Intrinsic Value
Not Available
A
Back to Top